PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
- New category targets programs that support the transition from adolescence to adulthood -
- Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.
/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate.
Share this article
Share this article
SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39
th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST. Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2020 accomplishments and highlight upcoming potential value-creating milestones. Preliminary 2020 unaudited financial results and 2021 financial guidance will also be provided. The presentation will be webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com.
Chief Executive Officer of Ptc Therapeutics, Inc. (NASDAQ:PTCT), Peltz Stuart Walter, sells 20,017 shares worth $1,229,484
According to Ptc Therapeutics, Inc. s most recent Statement Of Changes In Beneficial Ownership - Form 4 filing with the SEC dated Dec 09 07:52 PM, company Chief Executive Officer, Peltz Stuart Walter disclosed selling 20,017 shares at a cost of $61.42. At the time of this transaction (Dec 07), this trade was worth $1,229,484 in total. As of Dec 07, Peltz Stuart Walter now owns 56,085 shares in total worth about $3,476,709.15.
For the last few recent trades made by Ptc Therapeutics, Inc. (NASDAQ:PTCT) Chief Executive Officer, Peltz Stuart Walter, we have the following information: